Valion Bio, Inc. VBIO
3.03
(0.45)
(12.93%)
as of 25 Sep
- Market cap
- $3.0M
- P/E
- 0.0×
Follow VBIO
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (489.30%) | (198.48%) | (93.69%) | (178.21%) |
+8 more TTM periods Free account |
|
| (104.96%) | (66.64%) | (52.63%) | (156.02%) | ||
ROIC |
(61.01%) | (41.17%) | (26.95%) | (152.85%) | |
Return on Tangible Assets |
(153.07%) | (74.89%) | (36.22%) | (241.07%) | |
Average Days of Receivables |
— | — | — | 14.39 | |
Free Cash Flow per Share |
(108.54) | (96.84) | (164.07) | (115.34) | |
Free Cash Flow |
(14.67) | (11.17) | (7.58) | (6.09) | |
Capital Expenditures |
(0.10) | (0.04) | (0.58) | (0.01) | |
Piotroski F-Score |
— | — | — | 2.00 | |
| Other line items | |||||
Cash ROIC |
(68.17%) | (34.05%) | (16.18%) | (67.22%) | |
Accounts Receivable Turnover |
— | — | — | 34.43 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 1.91 | |
Inventory Turnover |
0.00 | 0.00 | — | 2.07 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 222.74 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | 1.92 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 452.49% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 678.22% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 99.17% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | 0.79 | 0.77 | 0.81 | |
Depreciation/Fixed assets |
0.15 | 0.06 | 0.01 | 22.92 | |
Capex/Depreciation |
(0.05) | (0.06) | (5.70) | (0.05) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 9.13 | |
Operating CF per Share |
(107.80) | (96.45) | (151.49) | (115.09) | |
Capex per Share |
(0.73) | (0.39) | (12.58) | (0.25) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.03 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (1,557.47%) |
Columns are period end dates